• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Big day loom­ing, No­var­tis' new CEO Vas Narasimhan read­ies his jump in­to a mar­ket­ing melee

8 years ago
Bioregnum
Opinion

When VCs hand out mega-rounds to Vir and Gos­samer, are they bet­ting on the jock­ey or the horse?

8 years ago
Financing
Startups

Reck­on­ing the po­ten­tial of CRISPR/Cas9 tech, NIH launch­es $190M genome edit­ing re­search ini­tia­tive

8 years ago
R&D
Discovery

Puma Biotech­nol­o­gy shares tank af­ter CHMP looks ready to hit a red light on ner­a­tinib

8 years ago
Pharma

In­cyte tries to fend off TR­C's mi­ni-ten­der of­fer to in­vestors; Grit­stone On­col­o­gy scoops Acte­lion CFO Jean-Marc ...

8 years ago
News Briefing

Pan­cre­at­ic can­cer com­bo sees high sur­vival rates in Chemo­Cen­tryx PhIb da­ta

8 years ago
R&D

J&J’s move to cut Rem­i­cade price cost some big bucks, but guard­ed against Pfiz­er’s copy­cat

8 years ago
R&D
Pharma

Al­lied with Penn, Tmu­ni­ty’s cell ther­a­py pi­o­neers bag $100M mega-round to back a break­through quest on CAR-T, ...

8 years ago
Startups

Lin­ing up against ri­vals, Am­gen and No­var­tis build a block­buster case for their CGRP mi­graine drug

8 years ago
R&D

Top 10 pipeline blowups, set­backs and sna­fus in H2 2017

8 years ago
Bioregnum
R&D

FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion

8 years ago
Pharma

Fast-grow­ing Gilead buys an R&D cam­pus for $135M — re­port; Eu­re­ka bags $60M round for T cell R&D work

8 years ago
News Briefing

Gov­ern­ment shut­down to end - at least tem­porar­i­ly - as Dems take Mc­Connell at his word

8 years ago
Pharma

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

8 years ago
Financing

Idera, Biocryst to merge, re­brand and fo­cus in rare dis­ease pro­grams

8 years ago
Deals

Hep­tares co-founder Fiona Mar­shall grabs the helm at Mer­ck­'s up­com­ing UK drug dis­cov­ery cen­ter

8 years ago
People

Cel­gene bags CAR-T play­er Juno in $9B buy­out as biotech M&A sud­den­ly ex­plodes

8 years ago
Deals

In the lat­est set­back to Vi­cal/Astel­las part­ner­ship, lead CMV vac­cine fails a piv­otal PhI­II study

8 years ago
R&D

Div­ing deep in­to the he­mo­phil­ia mar­ket, Sanofi strikes an $11.6B Biover­a­tiv buy­out

8 years ago
Deals

BeiGene ups of­fer­ing to a whop­ping $750M; Cel­gene back­ing $475M raise for Agios; Avastin copy­cat OK'd for Eu­rope

8 years ago
News Briefing

Big Phar­ma vet John Hohnek­er takes the reins at Anokion; Hep­tares co-founder Fiona Mar­shall re­signs from par­ent ...

8 years ago
Peer Review

Phar­ma­Mar stock tanks af­ter PhI­II ovar­i­an can­cer study flops

8 years ago
R&D

Drug­mak­ers take to Japan: 3 new drug ap­provals won by As­traZeneca, Mer­ck, and EA Phar­ma

8 years ago
Pharma

As­traZeneca gives it­self top marks for R&D pro­duc­tiv­i­ty makeover — but the ju­ry is still out

8 years ago
Bioregnum
R&D
First page Previous page 1055105610571058105910601061 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.